Hello, everybody, welcome back to Psychedelics today. This is one of our celebrated Friday episodes,

maybe soon to be rebranded. Still trying to figure that out. Kyle, how are you doing today? Pretty good,

Joe. How are you doing? Lovely. It's been snowing for a whole day. So I'm getting pretty psyched.

Beautiful, beautiful time of ice yeah that transition

yesterday it was all bare ground out my window no it's all covered sweet i just saw that uh my local

ski resort has projected opening date for december 10th i don't know if that's going to happen but

i'm getting excited yeah Yeah, outstanding. So

today we're doing something a little bit different from normal. We recorded a whole bunch of audio

and didn't want to kind of give you too many short episodes. Maybe you like that kind of thing,

but we want to do just a little bit of Solidarity Friday,

and we'll do a little bit of recorded interview. Today we have Peyton Nyquist. Is that his

name of Numenus, CEO of Numinous. Yeah. And interesting guy, really nice guy and really compelling

story. You weren't in the room for that one, right? No, I wasn't. Yeah.

Yeah, I really, really liked his energy, like what they're bringing to the table. It sounds like

there could be some really game-changing stuff coming from them. Canadian company. And get this, man,

like kind of lifelong chronic pain suffer. And we get into it a little bit and psychedelics just kind of

they just went away it's like huh that's interesting and that wasn't really what he went there for

and they're exploring that a little bit right i think so there's a few companies i think looking at

chronic pain maybe trip remap therapeutics trip remap therapeutics i trip, remap therapeutics, I think I just said that,

in Numinous, yeah. So like, there's, there's at least a few. I know there's a number of big deal

scientists working on the topic as well in universities. So hopefully we'll have some relief for folks

in a few years. That would be lovely.

...